2022 Liquid Biopsy Innovation Symposium
Tues, June 21, 2022
Virtual Sessions and Breakouts: 10am – 3pm ET
Liquid biopsy represents a significant, untapped market for our coverage. Advances in science are opening several new clinical applications for genomics across cancer screening, minimal residual disease (MRD) testing and comprehensive genomic profiling (CGP). There is a very wide range of outcomes – with the potential to transform healthcare diagnosis and treatment in a bull case, and clinical & commercial risks in the downside case.
Nephron Research’s Liquid Biopsy Symposium is here to help you digest the big debates which will influence the market opportunity for liquid biopsy.
- The event features a diverse set of opinions from the leading innovators across public and private companies
- In addition, we’ll be joined by leading experts to address the key debates around clinical data, reimbursement and regulatory pathways to commercialization.
- Participating companies include Exact Sciences (EXAS), Guardant Health (GH), Biological Dynamics (private) and Delfi (private)
- We conclude the day with a keynote discussion with Dr. Stephen Hahn, CEO of Harbinger Health (private) and former Commissioner of the FDA
Email firstname.lastname@example.org for details on attendance.